Mozilla Seabird 2D

The future of the smart phone. An interesting concept from Mozilla Labs.

Google New

Google New is one place to find everything new about Google.

Software Patents Hurt Everyone, But Especially SMBs - PCWorld Business Center

Software Patents Hurt Everyone, But Especially SMBs - PCWorld Business Center

It's the little guys who are getting hurt most by this curse of software patents.

Indian shares start month on front foot; techs lead | Reuters

Tech stocks are leading: Indian shares start month on front foot; techs lead | Reuters

Cognizant used slowdown as an opportunity to grow - Services & Apps - Enterprise IT - Tech - The Times of India

Cognizant used slowdown as an opportunity to grow - Services & Apps - Enterprise IT - Tech - The Times of India

In the three months ended June 2010, Cognizant has narrowed its revenue gap with Wipro to a mere $99 million. In an interview, D'Souza says he never looks at the rear view. Speaking about the dangers of protectionism, he describes America's Border Security Bill as unfortunate.

Read more: Cognizant used slowdown as an opportunity to grow - Services & Apps - Enterprise IT - Tech - The Times of India http://timesofindia.indiatimes.com/tech/enterprise-it/services-apps/Cognizant-used-slowdown-as-an-opportunity-to-grow-/articleshow/6468757.cms#ixzz0yHOIFyNA

Software patent wars are killing innovation | IT PRO

Cooment on: Software patent wars are killing innovation | IT PRO

Paul Allen's recent suite is another indicator of all that is wrong with software patents.

Indian companies are left with limited choice - Economy and Politics - livemint.com

Indian companies are left with limited choice - Economy and Politics - livemint.com

In a Siemens-Mint discussion on “Building the India Advantage: Global Competitiveness and Global Markets”, Tarun Khanna, the Jorge Paulo Lemann professor at Harvard Business School; R. Gopalakrishnan, executive director, Tata Sons Ltd; Partha Bhattacharyya, chairman, Coal India Ltd; and Glenn Saldanha, managing director and chief executive officer, Glenmark Pharmaceuticals Ltd; spoke on the issue. R. Sukumar, editor, Mint, moderated the discussion.